Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.
Cyclopharm’s flagship lung imaging agent Technegas has been explicitly recognised as a preferred ventilation agent in a new draft ventilation–perfusion (V/Q) pulmonary scintigraphy guideline developed for leading US and international nuclear medicine societies. The draft, which marks the first major update to US-aligned lung imaging guidance since 2012, cites Technegas as generally preferred where available and highlights its role in enhancing diagnostic accuracy and expanding applications beyond pulmonary embolism to a range of respiratory and cardiothoracic indications, a move expected to accelerate US clinical demand, support broader institutional adoption and strengthen Technegas’ positioning in hospital procurement and reimbursement decisions.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.88 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that services the global medical community, focusing on nuclear medicine solutions to improve patient outcomes. Its core product, Technegas, is an advanced functional lung ventilation imaging agent based on technetium-99m-labelled carbon particles, historically used to diagnose pulmonary embolism and increasingly applied in conditions such as COPD, asthma, pulmonary hypertension and in interventional lung procedures.
Average Trading Volume: 62,635
Technical Sentiment Signal: Sell
Current Market Cap: A$97.8M
Learn more about CYC stock on TipRanks’ Stock Analysis page.